We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP Inhibitors and Proteins Interacting with SLX4.
- Authors
Jordheim, Lars Petter
- Abstract
Simple Summary: The aim of this review is to highlight recent work performed on the activity of a class of cancer drugs (PARP inhibitor) in various cell lines, either expressing or not expressing proteins interacting with the DNA repair protein SLX4. This could be at the basis of the development of new therapeutic strategies in cancer treatment. PARP inhibitors are small molecules currently used with success in the treatment of certain cancer patients. Their action was first shown to be specific to cells with DNA repair deficiencies, such as BRCA-mutant cancers. However, recent work has suggested clinical interest of these drugs beyond this group of patients. Preclinical data on relationships between the activity of PARP inhibitors and other proteins involved in DNA repair exist, and this review will only highlight findings on the SLX4 protein and its interacting protein partners. As suggested from these available data and depending on further validations, new treatment strategies could be developed in order to broaden the use for PARP inhibitors in cancer patients.
- Subjects
TUMOR genetics; THERAPEUTIC use of antineoplastic agents; SMALL molecules; GENETIC mutation; BRCA genes; PROTEOMICS; METABOLIC disorders; GENE expression profiling; TUMORS; CELL lines; RECOMBINANT DNA; DNA repair; ENZYME inhibitors; RECOMBINANT proteins
- Publication
Cancers, 2023, Vol 15, Issue 3, p997
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers15030997